• Oralair: Oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product. Oralair is approved for use in person 10 through 65 years of age.
• Ragwitek: For the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age.
• Grastek: Grastek is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. Grastek is approved for use in person 5 through 65 years of age.

• Diagnosis of allergic rhinitis

AND

• Prescribed by an allergist or immunologist

AND

• Positive skin test or in vitro testing for pollen-specific IgE antibodies for allergens based on the requested drug (Ragwitek: short rageweed pollen, Grastek: Timothy grass or cross reactive species [Sweet vernal, Meadow fescue, Rye, June, Kentucky blue, Orchard, Red top, Velvet, Canary, Cereal grains (e.g., wheat, rye, barley)], Oralair: Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass)

AND

• Failure or clinically significant adverse effects to 2 of the following: oral antihistamines, leukotriene modifiers or nasal steroids
  

• Non-FDA approved indications, which are not listed in the Health Net Approved Indications and Usage Guidelines section, unless there is sufficient documentation of efficacy and safety in the published literature.
• Severe, unstable or uncontrolled asthma
• History of any severe allergic reaction to allergen immunotherapy

• Oralair is contraindicated in the following patients: Severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy and/or hypersensitivity to any of the inactive ingredients contained in this product.
• Oralair can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema. Patients should have immediate access to an auto-injectable epinephrine and instructed and trained on its appropriate use
• The initial dose must be administered in a healthcare setting under the supervision of a physician prepared to manage a severe systemic or a severe local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of Oralair.
• Oralair may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction
• Oralair may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.
• The safety and efficacy of Oralair 300IR in the pediatric population older than 5 years of age was demonstrated in a randomized clinical trial.

Oralair Sublingual Tablets: 100 IR and 300 IR
Ragwitek: Tablet 12 Amb a 1-Unit (Amb a 1-U)
Grastek: Sublingual Tablet 2800 BAU